Market Cap 1.03B
Revenue (ttm) 49.80M
Net Income (ttm) -50.34M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -101.08%
Debt to Equity Ratio 0.24
Volume 6,251,400
Avg Vol 2,768,122
Day's Range N/A - N/A
Shares Out 444.20M
Stochastic %K 88%
Beta 0.97
Analysts Sell
Price Target $3.36

Company Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospit...

Industry: Biotechnology
Sector: Healthcare
Phone: 281 863 3000
Fax: 281 863 8088
Address:
2445 Technology Forest Boulevard, 11th Floor, The Woodlands, United States
AlanOnTheBeat
AlanOnTheBeat May. 13 at 10:06 AM
Lots of small cap stocks are recovering in premarket after yesterday. $LXRX usually is active on market open. We might see another jump.
0 · Reply
atreus57
atreus57 May. 12 at 11:39 PM
$LXRX pretty much any news will be positive news, we know that... and pretty much any positive news now would accelerate this stock's growth by 3 dollars each, and we have how many positive news waiting? 4? This is going to be huge! HUGE!
0 · Reply
Iman133
Iman133 May. 12 at 10:18 PM
2 · Reply
gucag006
gucag006 May. 12 at 9:49 PM
$LXRX Rushing against Getting Too Old - 3 9) Novo is relatively weak in heart diseases with GLP-1's NNT around 60; 9) Inpefa for HF and HCM should be a very attractive asset for Novo with NNT=4 and HCM potential; 10) Then there is another drug with blockbuster potential - Pilavapadin, for DPNP, which is ready for a partnered phase 3 clinical trial; 11) Pilavapadin's story as a non-opioid pain killer is only the beginning, and numerous pain indications are waiting in line to be tested such as spasticity, Postherpetic Neuralgia (PHN), chemotherapy-induced peripheral neuropathy (CIPN), and postherpetic neuralgia, and MS-related pain. Novo Nordisk is high on GLP-1 success now, and from many different angles, Lexi's LX9851, Sotagliflozin, LX9211, and Genome5000 durg candidates look more and more like a good fit. My 2-cents, anyway. GLTA!
2 · Reply
gucag006
gucag006 May. 12 at 9:30 PM
$LXRX Rushing against Getting Too Old - 2 So, this is what I think RD has done and is contemplating: 1) Targeting Novo Nordisk - a Danish BP (Ray from Lebanon with European affinity); 2) Novo has committed $1B to develop LX9851; 3) Novo Foundation is testing cash cow, GLP-1 drug along with Sotagliflozin in Steno1&2 trials; (GLP-1 drugs rack in $33B for Novo in 2025); 4) FDA officially told Lexi that Steno1's data cut (in safety and exposure) can support Zynqusita/T1D NDA resubmission; 5) Zynquista /T1D resubmission is imminent according to Exton during last ER - in weeks with approval by the end of 2026; 6) Zynquista as an adjunct med with insulin will be a blockbuster drug with peak annual sale exceed $1B; 7) Novo is also a global leader in synthetic insulin with sales over $5.8B in 2025 with deeply trenched WW sales forces; 8) A packaged sale of insulin with Sota for the quality of life improvement for T1D patients should extend and expand Novo's insulin markets; (to be continued)
0 · Reply
Hatrak1
Hatrak1 May. 12 at 9:27 PM
$LXRX Something to think about ? 🤷‍♂️🤔👀
0 · Reply
Hatrak1
Hatrak1 May. 12 at 9:14 PM
$LXRX Did a little digging and the loans are not exactly the same. 🤷‍♂️
0 · Reply
gucag006
gucag006 May. 12 at 9:00 PM
$LXRX Rushing against Getting Too Old - 1 I cannot imagine that RD is planning to organically grow Lexi to its maturity, which will take another 5 to 10 year before Lexi fully establishes the sustainable business model with significant revenue and profits. At 71, RD is running Artal/Invus for the Belgian sugar beet tycoon Eric Wittouck, age 79 with $9B ranked #392 on Forbes billionaire list. Eric lives in Monaco and have 4 children. In 5 years, Eric will be 84, and his children should be in their 50s and 60s. RD helped Eric climb his billionaire ladder, and the final push will get him over $10B or even to $15B. Both RD and Eric Whttouck family, IMO, don't have the patience for another 5 to 10 years, and when you divide $10B by 5, the # is not that impressive anymore in their circle. So, the pressure must be on. This leads me to guess what RD's up to ..... (To be continued)
2 · Reply
Hatrak1
Hatrak1 May. 12 at 8:53 PM
$LXRX This is the second time I've seen this type of loan deal and seems the same type situations. Both companies on the verge of acquisition / partnership / trial data. Those warrants were issued with a 5 yr grace period and only for moneys taken on the loan. Are they a way of paying the debt in the future ? Were the loans given with the knowledge of insider info ? If they do pay for the loan plus profit then it would offset the dilution wouldn't it ? Does it make sense that Lexicon would pay Prime + 3.1% + 1.59 per share for a loan ? Pretty freaking expensive loan, wouldn't you say ? 🤷‍♂️
1 · Reply
KurwaMac
KurwaMac May. 12 at 8:31 PM
$LXRX IMO gonna start drifting towards low $2’s unless news comes. Buying op.
2 · Reply
Latest News on LXRX
Lexicon price target raised to $3.10 from $2.30 at Citi

2026-05-11T11:01:50.000Z - 2 days ago

Lexicon price target raised to $3.10 from $2.30 at Citi


Lexicon Pharmaceuticals Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 5 days ago

Lexicon Pharmaceuticals Earnings Call Transcript: Q1 2026


Lexicon, Novo Nordisk announce initiation of LX9851 study

2026-03-23T11:46:37.000Z - 7 weeks ago

Lexicon, Novo Nordisk announce initiation of LX9851 study

NVO


Lexicon price target raised to $2.30 from $2.10 at Citi

2026-03-10T10:53:36.000Z - 2 months ago

Lexicon price target raised to $2.30 from $2.10 at Citi


Lexicon price target raised to $6 from $4 at H.C. Wainwright

2026-03-05T16:06:30.000Z - 2 months ago

Lexicon price target raised to $6 from $4 at H.C. Wainwright


Lexicon Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:30 AM EST - 2 months ago

Lexicon Pharmaceuticals Earnings Call Transcript: Q4 2025


Lexicon reports Q4 EPS (4c), consensus (7c)

2026-03-05T12:08:49.000Z - 2 months ago

Lexicon reports Q4 EPS (4c), consensus (7c)


Lexicon announces common stock offering, no amount given

2026-01-29T21:36:16.000Z - 3 months ago

Lexicon announces common stock offering, no amount given


Lexicon Announces Proposed Public Offering of Common Stock

Jan 29, 2026, 4:31 PM EST - 3 months ago

Lexicon Announces Proposed Public Offering of Common Stock


Lexicon price target raised to $2.10 from $1.90 at Citi

2026-01-14T10:45:10.000Z - 4 months ago

Lexicon price target raised to $2.10 from $1.90 at Citi


Lexicon sees cash runway into 2027

2026-01-12T12:55:44.000Z - 4 months ago

Lexicon sees cash runway into 2027


Lexicon publishes White Paper on treatments for chronic pain

2026-01-09T13:40:14.000Z - 4 months ago

Lexicon publishes White Paper on treatments for chronic pain


Lexicon announces publication of preclinical data on ACSL5

2025-12-10T13:40:17.000Z - 5 months ago

Lexicon announces publication of preclinical data on ACSL5

NVO


Lexicon Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 6 months ago

Lexicon Pharmaceuticals Earnings Call Transcript: Q3 2025


Lexicon reports Q3 EPS (4c), consensus (7c)

2025-11-06T12:41:13.000Z - 6 months ago

Lexicon reports Q3 EPS (4c), consensus (7c)


Lexicon Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 9 months ago

Lexicon Pharmaceuticals Earnings Call Transcript: Q2 2025


Lexicon Pharmaceuticals Earnings Call Transcript: Q1 2025

May 13, 2025, 5:00 PM EDT - 1 year ago

Lexicon Pharmaceuticals Earnings Call Transcript: Q1 2025


AlanOnTheBeat
AlanOnTheBeat May. 13 at 10:06 AM
Lots of small cap stocks are recovering in premarket after yesterday. $LXRX usually is active on market open. We might see another jump.
0 · Reply
atreus57
atreus57 May. 12 at 11:39 PM
$LXRX pretty much any news will be positive news, we know that... and pretty much any positive news now would accelerate this stock's growth by 3 dollars each, and we have how many positive news waiting? 4? This is going to be huge! HUGE!
0 · Reply
Iman133
Iman133 May. 12 at 10:18 PM
2 · Reply
gucag006
gucag006 May. 12 at 9:49 PM
$LXRX Rushing against Getting Too Old - 3 9) Novo is relatively weak in heart diseases with GLP-1's NNT around 60; 9) Inpefa for HF and HCM should be a very attractive asset for Novo with NNT=4 and HCM potential; 10) Then there is another drug with blockbuster potential - Pilavapadin, for DPNP, which is ready for a partnered phase 3 clinical trial; 11) Pilavapadin's story as a non-opioid pain killer is only the beginning, and numerous pain indications are waiting in line to be tested such as spasticity, Postherpetic Neuralgia (PHN), chemotherapy-induced peripheral neuropathy (CIPN), and postherpetic neuralgia, and MS-related pain. Novo Nordisk is high on GLP-1 success now, and from many different angles, Lexi's LX9851, Sotagliflozin, LX9211, and Genome5000 durg candidates look more and more like a good fit. My 2-cents, anyway. GLTA!
2 · Reply
gucag006
gucag006 May. 12 at 9:30 PM
$LXRX Rushing against Getting Too Old - 2 So, this is what I think RD has done and is contemplating: 1) Targeting Novo Nordisk - a Danish BP (Ray from Lebanon with European affinity); 2) Novo has committed $1B to develop LX9851; 3) Novo Foundation is testing cash cow, GLP-1 drug along with Sotagliflozin in Steno1&2 trials; (GLP-1 drugs rack in $33B for Novo in 2025); 4) FDA officially told Lexi that Steno1's data cut (in safety and exposure) can support Zynqusita/T1D NDA resubmission; 5) Zynquista /T1D resubmission is imminent according to Exton during last ER - in weeks with approval by the end of 2026; 6) Zynquista as an adjunct med with insulin will be a blockbuster drug with peak annual sale exceed $1B; 7) Novo is also a global leader in synthetic insulin with sales over $5.8B in 2025 with deeply trenched WW sales forces; 8) A packaged sale of insulin with Sota for the quality of life improvement for T1D patients should extend and expand Novo's insulin markets; (to be continued)
0 · Reply
Hatrak1
Hatrak1 May. 12 at 9:27 PM
$LXRX Something to think about ? 🤷‍♂️🤔👀
0 · Reply
Hatrak1
Hatrak1 May. 12 at 9:14 PM
$LXRX Did a little digging and the loans are not exactly the same. 🤷‍♂️
0 · Reply
gucag006
gucag006 May. 12 at 9:00 PM
$LXRX Rushing against Getting Too Old - 1 I cannot imagine that RD is planning to organically grow Lexi to its maturity, which will take another 5 to 10 year before Lexi fully establishes the sustainable business model with significant revenue and profits. At 71, RD is running Artal/Invus for the Belgian sugar beet tycoon Eric Wittouck, age 79 with $9B ranked #392 on Forbes billionaire list. Eric lives in Monaco and have 4 children. In 5 years, Eric will be 84, and his children should be in their 50s and 60s. RD helped Eric climb his billionaire ladder, and the final push will get him over $10B or even to $15B. Both RD and Eric Whttouck family, IMO, don't have the patience for another 5 to 10 years, and when you divide $10B by 5, the # is not that impressive anymore in their circle. So, the pressure must be on. This leads me to guess what RD's up to ..... (To be continued)
2 · Reply
Hatrak1
Hatrak1 May. 12 at 8:53 PM
$LXRX This is the second time I've seen this type of loan deal and seems the same type situations. Both companies on the verge of acquisition / partnership / trial data. Those warrants were issued with a 5 yr grace period and only for moneys taken on the loan. Are they a way of paying the debt in the future ? Were the loans given with the knowledge of insider info ? If they do pay for the loan plus profit then it would offset the dilution wouldn't it ? Does it make sense that Lexicon would pay Prime + 3.1% + 1.59 per share for a loan ? Pretty freaking expensive loan, wouldn't you say ? 🤷‍♂️
1 · Reply
KurwaMac
KurwaMac May. 12 at 8:31 PM
$LXRX IMO gonna start drifting towards low $2’s unless news comes. Buying op.
2 · Reply
gucag006
gucag006 May. 12 at 8:23 PM
$LXRX Reposting to attact more eyeballs .....
1 · Reply
sabill
sabill May. 12 at 8:12 PM
$LXRX In one way, I'm as impressed with today's SP action as yesterday and Friday. Those other moves were great. Don't get me wrong. But today gave some an opportunity to book profits and then pulled back. But then the market absorbed the selling and moved back up toward the closing. I've been trying to find a posting I made months ago about option expiry at $2.00 and then, ha ha, maybe $2.50. It was a tongue in cheek quip. But surprise to me, this Friday is starting to look very interesting.
1 · Reply
liloleme4
liloleme4 May. 12 at 7:50 PM
$LXRX Another nice day for Lexi! Nowhere near yesterday's volume, but still a decent number trading hands - and upward. All positive IMO. I actually expected a pullback today
0 · Reply
Lagoule
Lagoule May. 12 at 7:19 PM
$LXRX Institutional Ownership ‼️🤩
0 · Reply
Lagoule
Lagoule May. 12 at 7:17 PM
$LXRX OMG! Inside Ownership ‼️😱🤩👍
1 · Reply
Achouffe
Achouffe May. 12 at 7:13 PM
$LXRX Long legs she has. Reminder > FUSN 2.0
0 · Reply
Lagoule
Lagoule May. 12 at 7:05 PM
$LXRX 😝 Let’s Go! 💥🚀📈
1 · Reply
bened1ctxvii
bened1ctxvii May. 12 at 6:57 PM
$LXRX yeahhhhh… loading before close rather than pulling.
0 · Reply
Salishseas
Salishseas May. 12 at 6:56 PM
0 · Reply
SniperPro
SniperPro May. 12 at 6:17 PM
$LXRX RELOAD, SIMPLE! RINSE AND REPEAT. DO IT UNTIL END OF TIMES!
1 · Reply
Lagoule
Lagoule May. 12 at 5:59 PM
$LXRX I had completely forgotten that I held this in my Roth account too, but it was sold this morning for $2.50. It looks like I placed that limit order a very long time ago. 😱😁
2 · Reply
SniperPro
SniperPro May. 12 at 5:53 PM
$LXRX F.D.A. Commissioner Marty Makary Resigns After Weeks of Pressure.... The agency’s top food official will step in as acting commissioner, after Dr. Makary’s tumultuous run as the nation’s top food, drug, tobacco and medical device regulator. https://www.nytimes.com/2026/05/12/us/politics/trump-fires-fda-commissioner-makary.html
0 · Reply